Aptose Biosciences Down 5% in U.S. Premarket, Initiates Study for Newly Diagnosed AML Patients
Aptose Biosciences Down 5% in U.S. Premarket, Initiates Study for Newly Diagnosed AML Patients
aptose biosciences在美国盘前交易下跌5%，启动针对新诊断急性髓性白血病患者的研究
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间